BPC-157, TB-500 (Blend)

Yıldırım AK, Demirtaş H, Özer A, Arslan M

Scientific reports

In a rat model of lower-limb ischemia-reperfusion injury, intraperitoneal BPC-157 reduced oxidative-stress markers (MDA, TOS) and apoptosis markers (p53, Bax, Caspase-3), restored antioxidant capacity (SOD, TAS), reduced IL-6 and Caspase-3 immunoreactivity, and partially restored VEGF expression, with histology showing improved muscle architecture and reduced collagen deposition versus the untreated ischemia-reperfusion group.

Mendias CL, Awan TM

Sports medicine (Auckland, N.Z.)

This narrative review surveys pharmacological mechanisms and preclinical tissue-repair evidence for research peptides used in musculoskeletal-injury and sports-medicine research, including BPC-157 and TB-500 (a thymosin beta-4 fragment), reporting favorable outcomes in animal models.

Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, et al.

Pharmaceuticals (Basel, Switzerland)

This review synthesizes rat-model evidence on stable gastric pentadecapeptide BPC-157 across tendon, ligament, and muscle injury models, including osteotendinous and myotendinous junction repair, reporting cytoprotective activity following both systemic (intraperitoneal, intragastric, oral) and local administration routes across multiple experimental designs.

Dubé KN, Smart N

Expert opinion on biological therapy

This review describes thymosin beta-4 (the parent protein of the TB-500 peptide fragment) as an actin-monomer-binding protein involved in vasculogenesis, angiogenesis, and endothelial-to-mesenchymal transition in developmental and injury models, noting that exogenous application enhances capillary formation and pericyte recruitment in preclinical vascular-repair studies.

Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al.

Journal of molecular medicine (Berlin, Germany)

Using chick chorioallantoic membrane and endothelial tube-formation assays plus a rat hind-limb ischemia model, BPC-157 increased vessel density and blood-flow recovery via up-regulation and internalization of VEGFR2 and activation of the VEGFR2-Akt-eNOS signaling pathway in vascular endothelial cells, identifying a mechanistic basis for its pro-angiogenic activity in vitro and in vivo.